International Journal of Multidisciplinary Engineering in Current Research - IJMEC
Volume 10, Issue 1, January-2025, http://ijmec.com/, ISSN: 2456-4265

PHARMACOLOGICAL INTERVENTIONS FOR CARDIOVASCULAR DISEASE: CURRENT STRATEGIES AND FUTURE DIRECTIONS

Gokul K. Khillare [1], Sonali Kalam [2], Dr. Gajanan Sanap [3]

Student, B. Pharm Final Year , Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Chha. Sambhaji Nagar, India .[1]

Asst. Prof, Department of Pharmaceutical Quality Assurance , Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Chha. Sambhaji Nagar, India.[2]

Principal, Department of Pharmaceutics, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Chha. Sambhaji Nagar, India.[3]

Abstract

Cardiovascular disease (CVD) remains the leading cause of global morbidity and mortality, necessitating innovative and effective management strategies. Pharmacological interventions are central to mitigating risk factors such as hypertension, dyslipidemia, and thrombosis, while emerging therapies offer avenues to target molecular pathways implicated in CVD pathophysiology. Current approaches, including antihypertensives, statins, antiplatelets, and anticoagulants, have significantly reduced disease burden but face limitations in adherence, accessibility, and individualized therapy. Novel agents, such as PCSK9 inhibitors, sodium-glucose co-transporter-2 (SGLT2) inhibitors, and interleukin-1β antagonists, represent a paradigm shift toward precision medicine. Emerging technologies, including RNA-based therapeutics, nanotechnology-driven drug delivery, and gene-editing tools like CRISPR, further highlight the transformative potential of personalized and preventive care. This review synthesizes advancements in pharmacological treatments for CVD, emphasizing the integration of digital health innovations and biomarker-guided therapies to enhance efficacy and safety. A comparative analysis of traditional and emerging strategies underscores the critical need for cost-effective solutions and equitable healthcare access. These findings aim to guide clinicians and researchers in optimizing therapeutic outcomes and addressing future challenges in CVD management.

Key words: *Cardiovascular disease, Lipid-lowering agents, Pharmacogenomics, Artificial intelligence (AI) and machine learning, Gene therapy (CRISPR).*

1.INTRODUCTION

Cardiovascular disease (CVD) remains the leading global cause of morbidity and mortality, responsible for approximately 20 million deaths annually [1]. As a multifaceted health challenge, CVD encompasses conditions such as coronary artery disease, heart failure, and stroke, significantly impacting public health and economic systems worldwide [2]. Addressing this burden requires effective prevention and treatment strategies, with pharmacological interventions forming a cornerstone of CVD management. Pharmacological treatments have revolutionized CVD management, offering mechanisms to modulate risk factors such as hypertension, dyslipidemia, and thrombosis. These therapies include antihypertensives, statins, antiplatelets, anticoagulants, and novel agents such

as PCSK9 inhibitors and SGLT2 inhibitors. Despite their efficacy, gaps persist in accessibility, adherence, and individualized therapy [3,4].

This review aims to provide an overview of current pharmacological strategies for CVD, explore emerging therapeutic modalities, and highlight future research directions. By synthesizing the latest evidence, we aim to guide clinicians and researchers in improving outcomes and reducing the global burden of CVD.

2. PATHOPHYSIOLOGY OF CARDIOVASCULAR DISEASES

Atherosclerosis: Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipid-laden plaques within arterial walls. This process is initiated by endothelial injury, followed by the recruitment of monocytes and transformation into foam cells. Plaque rupture leads to thrombosis and acute cardiovascular events. Key molecular targets for intervention include:

LDL Receptors: Statins lower LDL cholesterol, reducing plaque formation.

PCSK9: Inhibitors like evolocumab enhance LDL receptor recycling.

Inflammatory Cytokines: IL-1β inhibition with canakinumab reduces systemic inflammation [5].

Hypertension: Hypertension stems from increased systemic vascular resistance, often linked to endothelial dysfunction and imbalances in the renin-angiotensin-aldosterone system (RAAS). Elevated angiotensin II levels contribute to vasoconstriction and sodium retention. Pharmacological targets include:

RAAS Blockers: ACE inhibitors (enalapril) and ARBs (losartan).

Calcium Channels: Dihydropyridine calcium channel blockers lower arterial pressure [6].

Thrombosis: Thrombosis arises from hypercoagulable states and endothelial disruption, leading to fibrin and platelet aggregation. Key interventions target:

Platelets: Aspirin and P2Y12 inhibitors (clopidogrel) prevent aggregation.

Coagulation Cascade: Direct oral anticoagulants (DOACs) like apixaban inhibit factor Xa [7].

Heart Failure: Heart failure (HF) results from impaired myocardial function leading to insufficient systemic perfusion. Pathophysiological features include maladaptive neurohormonal activation, such as excessive RAAS and sympathetic nervous system activity. Pharmacological strategies involve:

Neprilysin Inhibitors: Sacubitril in combination with valsartan reduces neurohormonal effects.

Beta-blockers: Carvedilol mitigates cardiac workload [8].

Key Molecular Target	Pharmacological Interventions	Reference
Lipid Metabolism	• Statins (e.g., atorvastatin) inhibit HMG-CoA reductase. • PCSK9 inhibitors for enhanced LDL clearance.	[9]
RAAS Components	• ACE inhibitors and ARBs for vascular resistance. • Direct renin inhibitors, such as aliskiren.	[10]
Coagulation and Platelet Activation		[11]

	• Anticoagulants (e.g., warfarin, DOACs). • Anti-platelet therapies like aspirin.	
Inflammatory Mediators	• Cytokine-targeted therapies for reducing systemic inflammation. • Novel anti-inflammatory biologics under research.	[12]

Table no.1. Key Molecular Targets for Pharmacological Intervention

3. CURRENT PHARMACOLOGICAL STRATEGIES

3.1 Antihypertensive Drugs

3.1.1 Angiotensin-converting enzyme (ACE) inhibitors

ACE inhibitors reduce blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation and decreased aldosterone secretion. Drugs such as enalapril and ramipril are foundational in hypertension management and have shown benefits in heart failure and diabetic nephropathy [13,14].

3.1.2 Angiotensin II receptor blockers (ARBs)ARBs, including losartan and valsartan, block angiotensin II receptors, providing similar benefits to ACE inhibitors with reduced incidence of cough and angioedema. These agents are effective alternatives, especially in ACE inhibitor-intolerant patients [15,16].

3.1.3 Calcium channel blockers

Drugs like amlodipine and diltiazem inhibit calcium influx in vascular smooth muscle and myocardium, reducing systemic vascular resistance and heart rate. They are particularly effective in elderly patients and those with isolated systolic hypertension [17].

3.1.4 Beta-blockers

Beta-blockers (e.g., metoprolol, bisoprolol) decrease heart rate and myocardial contractility by antagonizing β-adrenergic receptors. They are pivotal in post-myocardial infarction management and heart failure with reduced ejection fraction (HFrEF) [18,19].

3.2 Lipid-Lowering Agents

3.2.1 Statins

Statins, such as atorvastatin and rosuvastatin, inhibit HMG-CoA reductase, reducing LDL cholesterol levels and cardiovascular events. They remain the cornerstone of dyslipidemia management [20,21].

3.2.2 PCSK9 inhibitors

Monoclonal antibodies like alirocumab and evolocumab target PCSK9, enhancing LDL receptor recycling and clearance of LDL cholesterol. These agents are reserved for high-risk patients inadequately managed with statins [22,23].

3.2.3 Bile acid sequestrants

Drugs like cholestyramine bind bile acids in the intestine, reducing LDL cholesterol. Although less effective than statins, they are useful in statin-intolerant patients [24].

3.3 Antithrombotic Therapy

3.3.1 Antiplatelet agents

Antiplatelet drugs, including aspirin and P2Y12 inhibitors (clopidogrel, ticagrelor), prevent platelet aggregation, reducing thrombotic events in coronary

artery disease and after percutaneous coronary interventions [25,26].

3.3.2Anticoagulants

Direct oral anticoagulants (DOACs) like rivaroxaban and apixaban, along with heparins, are critical in preventing thromboembolic events in atrial fibrillation and venous thromboembolism [27,28].

3.4 Drugs for Heart Failure

3.4.1 Diuretics

Loop diuretics (e.g., furosemide) and thiazide diuretics alleviate symptoms of fluid overload by promoting natriuresis. They are primarily symptomatic treatments [29].

3.4.2Mineralocorticoid recepto antagonists Drugs like spironolactone improve survival in HFrEF by antagonizing aldosterone's effects, reducing fibrosis and cardiac remodeling [30].

3.4.3 Angiotensin receptor-neprilysin inhibitors (ARNIs)

Sacubitril/valsartan, an ARNI, combines ARB activity with neprilysin inhibition, enhancing natriuretic peptides. It significantly improves survival in HFrEF patients [31].

3.4.4 Sodium-glucose co-transporter-2 (SGLT2) inhibitors

Originally developed for diabetes, SGLT2 inhibitors (dapagliflozin, empagliflozin) have shown cardiovascular and renal benefits in heart failure patients, irrespective of diabetes status [32].

3.5 Emerging Classes

3.5.1 Anti-inflammatory agents

Inflammation plays a critical role in atherosclerosis and CVD. Therapies targeting interleukin-1β (e.g., canakinumab) have demonstrated cardiovascular benefits in trials [33].

3.5.2 Omega-3 fatty acids

High doses of omega-3 fatty acids, such as icosapent ethyl, reduce cardiovascular events in high-risk populations with hypertriglyceridemia [34].

3.6 Combination Therapies

Fixed-dose combinations and polypills improve medication adherence by consolidating multiple agents into a single pill. Examples include combinations of ACE inhibitors with diuretics or statins with antihypertensives. Such strategies are particularly beneficial in low-resource settings [35,36].

4. CHALLENGES IN CURRENT PHARMACOLOGICAL TREATMENTS

4.1. Drug Resistance and Efficacy Issues

Drug resistance represents a critical challenge in managing CVDs, particularly in conditions such as hypertension and hyperlipidemia. The variable patient response to standard therapies, influenced by genetic and environmental factors, limits drug efficacy. For instance, resistance to statins in lipid-lowering therapy occurs due to genetic polymorphisms affecting LDL receptor function, leading to suboptimal outcomes in some patients [37,38].Recent advancements in personalized medicine and pharmacogenomics aim to address these limitations by tailoring therapies to individual genetic profiles [39]. However, integrating these approaches into routine clinical practice remains an ongoing challenge.

4.2. Adverse Effects and Safety Concerns

Despite their effectiveness, pharmacological treatments for CVDs are often associated with adverse effects. For example, beta-blockers and diuretics commonly cause fatigue, electrolyte imbalances, and metabolic disturbances, which can lead to treatment discontinuation [40]. Moreover, anticoagulants, while crucial for preventing thromboembolic events, carry a significant risk of

bleeding complications, complicating their long-term use [41].Improving the safety profile of drugs through novel formulations and delivery systems is critical. Strategies like nanoparticle-based drug delivery have shown promise in enhancing therapeutic precision and minimizing off-target effects [42].

4.3. Cost and Accessibility

The high cost of innovative therapies, such as PCSK9 inhibitors for hypercholesterolemia, limits their accessibility, especially in low- and middle-income countries (LMICs) [43]. The economic burden of lifelong treatments for chronic conditions like hypertension and heart failure exacerbates health inequities.Efforts to lower drug costs, including generic manufacturing and government-subsidized programs, are essential. Additionally, advancing cost-effective therapeutic options, such as polypills combining multiple medications, could improve access while ensuring comprehensive management of CVD risk factors [44].

4.4. Poor Adherence to Treatment Regimens

Non-adherence to prescribed medications is a pervasive issue, often resulting in suboptimal clinical outcomes and increased healthcare costs. Factors contributing to poor adherence include complex dosing regimens, adverse effects, and lack of patient education [45].Digital health interventions, including mobile health applications and wearable devices, have emerged as innovative tools to improve adherence. These technologies provide real-time reminders, track medication use, and facilitate patient-provider communication, enhancing treatment compliance [46].

5. FUTURE DIRECTIONS IN PHARMACOLOGICAL INTERVENTIONS

5.1 Precision Medicine

Role of Genetics and Biomarkers in Personalized Therapies: Advancements in genomics and proteomics have paved the way for precision medicine in CVD treatment. By identifying genetic polymorphisms and biomarkers, therapies can be tailored to individual patient profiles, improving efficacy and reducing adverse effects. For instance, the PCSK9 inhibitors alirocumab and evolocumab demonstrate the potential of targeted interventions in patients with familial hypercholesterolemia [47,48]. Pharmacogenomics continues to influence anticoagulation therapy, particularly with warfarin and direct oral anticoagulants (DOACs), emphasizing the need for personalized dosing [49].

5.2 Novel Drug Targets

RNA-based Therapeutics: RNA interference (RNAi) and messenger RNA (mRNA) therapies are emerging as potential tools for modulating gene expression associated with CVD. Inclisiran, a small interfering RNA (siRNA) targeting PCSK9, exemplifies the clinical application of RNA-based therapeutics in lowering LDL cholesterol levels [50].

Targeting Inflammation and Oxidative Stress: Chronic inflammation and oxidative stress contribute significantly to CVD pathogenesis. Therapies like canakinumab, an IL-1β inhibitor, have shown promise in reducing cardiovascular events in patients with elevated inflammatory markers [51]. Meanwhile, compounds targeting NADPH oxidase and scavenging reactive oxygen species (ROS) offer avenues for mitigating oxidative damage [52].

5.3 Advances in Drug Delivery

Nanotechnology-based Drug Carriers: Nanoparticles offer precise targeting and controlled drug release, enhancing the bioavailability of

cardiovascular therapeutics. For example, liposomal encapsulation of statins has demonstrated improved efficacy and reduced systemic toxicity in preclinical studies [53].

Biodegradable Implants for Sustained Release: Biodegradable stents and drug-eluting implants are increasingly used for localized and prolonged drug delivery in conditions like restenosis. Polymers like polylactic-co-glycolic acid (PLGA) have facilitated the sustained release of anti-proliferative agents [54].

5.4 Emerging Therapies

Gene Therapy and CRISPR-Based Interventions: Gene-editing tools like CRISPR-Cas9 hold transformative potential in treating genetic CVDs by directly correcting pathogenic mutations. Preclinical models of hypertrophic cardiomyopathy and familial hypercholesterolemia have demonstrated successful gene-editing outcomes [55].

Stem Cell-Derived Therapies: The use of induced pluripotent stem cells (iPSCs) offers regenerative potential for myocardial infarction and heart failure. While clinical trials have shown mixed results, ongoing research aims to optimize cell viability and integration [56].

5.5 Integration with Digital Health

Role of AI and Machine Learning in Optimizing Treatments: Artificial intelligence (AI) and machine learning are revolutionizing cardiovascular pharmacology by enabling predictive analytics and real-time treatment optimization. Algorithms trained on large datasets can identify patterns in patient responses, aiding in drug selection and dosage adjustments [57].

Use of Wearable Devices for Real-Time Monitoring: Wearable technologies, such as smartwatches and biosensors, provide continuous monitoring of vital signs and drug adherence. This real-time data integration enhances personalized management strategies, particularly in chronic CVD conditions [58].

6. COMPARATIVE ANALYSIS: CURRENT VS. EMERGING STRATEGIES

A comparison between current and emerging strategies in CVD management reveals significant advancements in efficacy, safety, and cost-effectiveness. Traditional approaches, such as beta-blockers and statins, provide effective symptom control but may lack precision and long-term sustainability. In contrast, emerging strategies, including RNA-based therapeutics and CRISPR, target the underlying molecular mechanisms of CVD.Additionally, while current pharmacological interventions are largely treatment-focused, emerging approaches emphasize prevention, driven by genetic insights and digital health tools. However, the high costs and technological complexities of new therapies pose challenges to widespread implementation. Addressing these barriers is crucial for transitioning from treatment to prevention-centric models [59,60].

7-CONCLUSION

Pharmacological interventions have significantly advanced the management of cardiovascular diseases, offering effective strategies to address key risk factors such as hypertension, dyslipidemia, thrombosis, and heart failure. Current therapies, including statins, antihypertensives, anticoagulants, and emerging agents like PCSK9 inhibitors and SGLT2 inhibitors, have improved clinical outcomes and reduced the global burden of CVD. However, challenges such as drug resistance, adverse effects, cost barriers, and treatment adherence persist, limiting their universal impact.Emerging

innovations in precision medicine, RNA-based therapeutics, and nanotechnology offer promising solutions to these challenges, emphasizing tailored treatments, improved drug delivery, and minimized systemic side effects. Additionally, advancements in gene therapy and CRISPR-based interventions provide opportunities to address genetic predispositions to CVD, while digital health technologies enhance patient monitoring and adherence. Despite these advancements, the integration of novel therapies into clinical practice remains hindered by economic and infrastructural disparities. Future efforts should focus on making these innovations accessible globally, alongside enhancing education and patient-centric care models. By bridging the gap between current limitations and emerging opportunities, the field of cardiovascular pharmacology can continue to evolve, ultimately improving patient outcomes and reducing the prevalence of cardiovascular diseases worldwide.

REFERENCES

1. Singh R, Chandi SK, Sran S, Aulakh SK, Nijjar GS, Singh K, Singh S, Tanvir FN, Kaur Y, Sandhu AP. Emerging Therapeutic Strategies in Cardiovascular Diseases. Cureus. 2024 Jul 12;16(7):e64388.
2. Narkhede M, Pardeshi A, Bhagat R, Dharme G. Review on Emerging Therapeutic Strategies for Managing Cardiovascular Disease. Current Cardiology Reviews. 2024 Jul 1;20(4):86-100.
3. Pearson TA, Feinberg W. Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease. Annals of Behavioral Medicine. 1997 Sep;19(3):230-8.
4. Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New England Journal of Medicine. 2003 Jan 30;348(5):383-93.
5. Severino P, D'Amato A, Pucci M, Infusino F, Adamo F, Birtolo LI, Netti L, Montefusco G, Chimenti C, Lavalle C, Maestrini V. Ischemic heart disease pathophysiology paradigms overview: from plaque activation to microvascular dysfunction. International journal of molecular sciences. 2020 Oct 30;21(21):8118.
6. Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart failure reviews. 2008 Sep;13:367-75.
7. Flora GD, Nayak MK. A brief review of cardiovascular diseases, associated risk factors and current treatment regimes. Current pharmaceutical design. 2019 Oct 1;25(38):4063-84.
8. Choi HM, Park MS, Youn JC. Update on heart failure management and future directions. The Korean journal of internal medicine. 2018 Dec 28;34(1):11.
9. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. Journal of the American College of Cardiology. 2010 Mar 30;55(13):1283-99.
10. Sarhene M, Wang Y, Wei J, Huang Y, Li M, Li L, Acheampong E, Zhengcan Z, Xiaoyan Q, Yunsheng X, Jingyuan M. Biomarkers in heart failure: the past, current and future. Heart failure reviews. 2019 Nov;24:867-903.
11. Wang CC, Hess CN, Hiatt WR, Goldfine AB. Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes–mechanisms,

management, and clinical considerations. Circulation. 2016 Jun 6;133(24):2459.

12. Wright JF. AAV vector manufacturing process design and scalability-Bending the trajectory to address vector-associated immunotoxicities. Molecular Therapy. 2022 Jun 1;30(6):2119-21.
13. DeFilippis EM, Beale A, Martyn T, Agarwal A, Elkayam U, Lam CS, Hsich E. Heart failure subtypes and cardiomyopathies in women. Circulation research. 2022 Feb 18;130(4):436-54.
14. Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies. Circulation research. 2019 Jan 4;124(1):121-41.
15. Krychtiuk KA, Gersh BJ, Washam JB, Granger CB. When cardiovascular medicines should be discontinued. European Heart Journal. 2024 Jun 14;45(23):2039-51.
16. Xu F, Mao C, Hu Y, Rui C, Xu Z, Zhang L. Cardiovascular effects of losartan and its relevant clinical application. Current medicinal chemistry. 2009 Oct 1;16(29):3841-57.
17. Kotchen TA. Historical trends and milestones in hypertension research: a model of the process of translational research. Hypertension. 2011 Oct;58(4):522-38.
18. Messerli FH, Bavishi C, Brguljan J, Burnier M, Dobner S, Elijovich F, Ferdinand KC, Kjeldsen S, Laffer CL, Ram CV, Rexhaj E. Renal denervation in the antihypertensive arsenal–knowns and known unknowns. Journal of hypertension. 2022 Oct 1;40(10):1859-75.
19. Chourdakis E, Koniari I, Velissaris D, Tsigkas G, Kounis NG, Osman N. Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives. Journal of Geriatric Cardiology: JGC. 2021 May 5;18(5):362.
20. Muzambi R, Bhaskaran K, Strongman H, Staa TV, Smeeth L, Herrett E. Trends and inequalities in statin use for the primary and secondary prevention of cardiovascular disease between 2009 and 2021 in England. medRxiv. 2024:2024-11.
21. Spector R, Snapinn SM. Statins for secondary prevention of cardiovascular disease: the right dose. Pharmacology. 2011 Jan 11;87(1-2):63-9.
22. Dullaart RP. PCSK9 inhibition to reduce cardiovascular events. New England Journal of Medicine. 2017 May 4;376(18):1790-1.
23. Schmidt AM. Diabetes mellitus and cardiovascular disease: Emerging therapeutic approaches. Arteriosclerosis, thrombosis, and vascular biology. 2019 Apr;39(4):558-68.
24. Zhang B, Kuipers F, de Boer JF, Kuivenhoven JA. Modulation of bile acid metabolism to improve plasma lipid and lipoprotein profiles. Journal of clinical medicine. 2021 Dec 21;11(1):4.
25. Marinelli EA, Arbelo E, Boriani G, Boveda S, Buckley CM, Camm AJ, Casadei B, Chua W, Dagres N, de Melis M, Desteghe L. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference.
26. Claassens DM, Vos GJ, Bergmeijer TO, Hermanides RS, Van't Hof AW, Van Der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. New England Journal of Medicine. 2019 Oct 24;381(17):1621-31.
27. Martin EM, Kondrat FD, Stewart AJ, Scrivens JH, Sadler PJ, Blindauer CA. Native

electrospray mass spectrometry approaches to probe the interaction between zinc and an anti-angiogenic peptide from histidine-rich glycoprotein. Scientific reports. 2018 Jun 5;8(1):8646.

28. Walenga JM, Jeske WP, Messmore HL. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. Journal of thrombosis and thrombolysis. 2000 Nov;10:13-20.
29. Felker GM. Loop diuretics in heart failure. Heart failure reviews. 2012 Mar;17:305-11.
30. Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Frontiers in cardiovascular medicine. 2022 Sep 27;9:933215.
31. Talha KM, Pandey A, Fudim M, Butler J, Anker SD, Khan MS. Frailty and heart failure: State-of-the-art review. Journal of Cachexia, Sarcopenia and Muscle. 2023 Oct;14(5):1959-72.
32. Diallo A, Carlos-Bolumbu M, Galtier F. Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: a systematic review and meta-analysis. EClinicalMedicine. 2022 Dec 1;54.
33. Calderone D, Ingala S, Mauro MS, Angiolillo DJ, Capodanno D. Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events. Expert Review of Cardiovascular Therapy. 2021 Dec 2;19(12):1097-117.
34. Cotter TG, Charlton M. Nonalcoholic steatohepatitis after liver transplantation. Liver Transplantation. 2020 Jan;26(1):141-59.
35. Underberg J, Toth PP, Rodriguez F. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgraduate Medicine. 2022 Nov 17;134(8):752-62.
36. Ruscica M, Ferri N, Santos RD, Sirtori CR, Corsini A. Lipid lowering drugs: present status and future developments. Current Atherosclerosis Reports. 2021 May;23:1-3.
37. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of cardiology. 2019 Sep 10;74(10):e177-232.
38. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, De Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019 Jun 25;73(24):3168-209.
39. Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nature Reviews Genetics. 2017 Jun;18(6):331-44.
40. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?. Journal of

the American College of Cardiology. 2018 Apr 3;71(13):1474-82.

41. Bochaton T, Paccalet A, Jeantet P, Crola Da Silva C, Cartier R, Prieur C, Jossan C, Bonnefoy-Cudraz E, Mewton N, Ovize M. Heat shock protein 70 as a biomarker of clinical outcomes after STEMI. Journal of the American College of Cardiology. 2020 Jan 7;75(1):122-4.
42. Liu Y, Yang G, Jin S, Xu G, Zhu Y, Xu D. Nanotechnology-based strategies for treatment of cardiovascular disease. *Nanomedicine*. 2020;24:102071. doi:10.1016/j.nano.2019.102071.
43. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. New England Journal of Medicine. 2015 Apr 16;372(16):1489-99.
44. Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, López-Jaramillo P, Yusoff K, Santoso A, Gamra H, Talukder S. Polypill with or without aspirin in persons without cardiovascular disease. New England Journal of Medicine. 2021 Jan 21;384(3):216-28.
45. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, Agoritsas T, Mistry N, Iorio A, Jack S, Sivaramalingam B. Interventions for enhancing medication adherence. Cochrane database of systematic reviews. 2014(11).
46. McConnell MV, Turakhia MP, Harrington RA, King AC, Ashley EA. Mobile health advances in physical activity, fitness, and atrial fibrillation: moving hearts. Journal of the American college of cardiology. 2018 Jun 12;71(23):2691-701.
47. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. New England Journal of Medicine. 2015 Apr 16;372(16):1500-9.
48. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. New England Journal of Medicine. 2015 Apr 16;372(16):1489-99.
49. Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal-Cardiovascular Pharmacotherapy. 2022 Jan 1;8(1):85-99.
50. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PL, Kastelein JJ. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. New England journal of medicine. 2020 Apr 16;382(16):1507-19.
51. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJ. Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England journal of medicine. 2017 Sep 21;377(12):1119-31.
52. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arteriosclerosis, thrombosis, and vascular biology. 2005 Jan 1;25(1):29-38.

53. Sghier K, Mur M, Veiga F, Paiva-Santos AC, Pires PC. Novel therapeutic hybrid systems using hydrogels and nanotechnology: a focus on nanoemulgels for the treatment of skin diseases. Gels. 2024 Jan 6;10(1):45.
54. Venkatraman SS, et al. Biodegradable stents with anti-proliferative agents. *Biomaterials.* 2008;29(22):2975-83.
55. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001 Oct 23;104(17):2007-11.
56. Van Linthout S, Stellos K, Giacca M, Bertero E, Cannata A, Carrier L, Garcia-Pavia P, Ghigo A, González A, Haugaa KH, Imazio M. State of the art and perspectives of gene therapy in heart failure. A scientific statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial & Pericardial Diseases. European journal of heart failure. 2024 Nov 1.
57. Correia CD, Ferreira A, Fernandes MT, Silva BM, Esteves F, Leitão HS, Bragança J, Calado SM. Human stem cells for cardiac disease modeling and preclinical and clinical applications—are we on the road to success?. Cells. 2023 Jun 27;12(13):1727.
58. Gutman R, Aronson D, Caspi O, Shalit U. What drives performance in machine learning models for predicting heart failure outcome?. European Heart Journal-Digital Health. 2023 May;4(3):175-87.
59. Wongvibulsin S, Martin SS, Steinhubl SR, Muse ED. Connected health technology for cardiovascular disease prevention and management. Current treatment options in cardiovascular medicine. 2019 Jun;21:1-5.
60. Tsao CW, Aday AW, Almarzooq ZI, Anderson CA, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, Commodore-Mensah Y. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023 Feb 21;147(8):e93-621.